The two agreements are with companies that are also active in the development of drugs for both liver and kidney fibrosis.
“The contracts with our new clients clearly show that pharmaceutical companies continue to invest in the development of new drugs for fibrosis, which is extremely promising for InfiCure Bio,” says InfiCure Bio’s CEO, Sofia Mayans. “This makes our preclinical model very interesting for them as they can evaluate the effect of their substance on both liver and kidney fibrosis at the same time. This is yet more proof of the need for and the potential of our model. The contracts with our new clients are an energy boost for the entire business, and it also shows that the pharmaceutical industry has rebooted again following the pandemic.”
“The pandemic showed us that it is extremely important to spread our risks and put more energy into finding clients in other parts of the world such as Europe as well.”
In parallel with the work on the projects for the new clients, InfiCure Bio is also working strategically to find more clients in the USA and Europe, the company states.
“Exciting times are ahead for us! Before the pandemic, our major focus was on the American market, but the pandemic showed us that it is extremely important to spread our risks and put more energy into finding clients in other parts of the world such as Europe as well,” says Sofia Mayans.
Photo of the InfiCure Bio team
